左洛复联合丹栀逍遥丸治疗卒中后抑郁的临床疗效

目的观察左洛复联合丹栀逍遥丸治疗卒中后抑郁的疗效与安全性。方法将本院收治的80例卒中后抑郁的患者根据随机原则分为观察组与对照组,每组40例。对照组给予左洛复治疗,观察组在对照组的基础上加用丹栀逍遥丸,治疗8周后,对两组患者的疗效与不良反应进行观察和记录。结果在治疗2、4、6、8周后,观察组的HAMD抑郁量表评分减分率均显著大于对照组,差异有统计学意义(t=4.571、3.317、3.971、3.348,P<0.05);治疗8周后,观察组的总有效率为97.5%,显著优于对照组(82.5%),差异具有统计学意义(χ2=5.00,P<0.05);观察组的不良反应发生率为7.5%,显著低于对照组(30%),差异具有统计学意义(χ2=6.65,P<0.05)。结论左洛复联合丹栀逍遥丸治疗卒中后抑郁疗效显著,不良反应少,值得临床推广。

Clinical Efficacy Observation of Zoloft Combined with Danzhixiaoyao Pills for the Treatment of Post-stroke Depression

Objective To observe the efficacy and safety of Zoloft combined with Danzhixiaoyao pills for the treatment of post-stroke depression. Methods 80 cases of patients with post-stroke depression received in our hospital were randomly divided into observation group and control group, with 40 cases in each group. Control group was given Zoloft, and the observation group was given Danzhixiaoyao pills based on the control group. Efficacy and adverse reactions in the two groups of patients were observed and recorded after 8 weeks of treatment. Results Reduced rate of HAMD scale scores in the observation group 2, 4, 6, 8 weeks after the treatment were significantly higher than the control group, the difference was statistically significant （t=4.571, 3.317, 3.971, 3.348,P〈0.05）;The total effective rate in observation group was 97.5%after 8 weeks of treatment, significantly better than the control group （82.5%）, the difference was statistically significant （χ2=5.00,P〈0.05）;Adverse reactions rate in observation was 7.5%, significantly lower than the control group （30%）, the difference was statistically significant （χ2=6.65,P〈0.05）. Conclusions Zoloft combined Danzhixiaoyao pills for the treatment of post-stroke depression had significant effect and less adverse reactions, worthy of clinical promotion.